Integration of Real-World Data into Clinical Trials: An Interdisciplinary Discussion from Regulatory and Practical Perspectives
Das Gesundheitswesen · 01.08.2026 · 88 (S 02 S 02) · S214-S219
DOI: 10.1055/a-2736-6561 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Das Gesundheitswesen, erschienen am 01.08.2026. Verfasst von Jeanette Köppe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Biometrie und Klinische Forschung, Universität Münster, Münster, Germany. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Clinical Trials as Topic. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Increasing efforts are required to integrate the growing volume of so-called real-world data (also named routine practice data), which are data generated outside of randomized controlled trials, into regulatory studies. Various stakeholders anticipate that such integration could save time and financial resources during the approval process of new therapies, and ethical considerations also partially support such an approach. The aim of this manuscript is to provide an overview of the methodological, ethical, and regulatory considerations when integrating routine practice data into randomized controlled trials. It targets clinical researchers, biostatisticians, regulators, and decision-makers involved in evidence generation and trial design. The inclusion of real-world data in randomized controlled trials can be meaningful from both ethical and economic perspectives. However, implementing this requires addressing various and sometimes significant limitations of the data, which need to be methodologically addressed. Therefore, it is essential to carefully weigh the risks and benefits of incorporating real world data into clinical studies. Randomized trials remain the gold standard for evaluating the efficacy of new therapies. Nevertheless, real-world data have the potential to improve the complex and costly process of drug development. The assessment of the potential for a specific clinical study should be made in collaboration with all relevant stakeholders. Apart from that, real-world data have a substantial potential to expand the evidence from randomized trials after post-market approval, thereby ensuring the safety of all patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institut für Biometrie und Klinische Forschung, Universität Münster, Münster, Germany.
- Department of Health Economy, Norwegian Medical Products Agency, Oslo, Norway.
- Clinical Statistics and Analytics, Bayer AG, Berlin, Germany.
- Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Medizinische Fakultät der Universität des Saarlandes, Homburg, Germany.
- Global Biostatistics, Merck Healthcare KGaA, Darmstadt, Germany.
- Abteilung Biostatistik, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Zitieren
APA
Köppe, J., Schiel, A., Gerlinger, C., Götte, H., Edelmann, D., & Erdmann, S. (2026). Integration of Real-World Data into Clinical Trials: An Interdisciplinary Discussion from Regulatory and Practical Perspectives. Das Gesundheitswesen, 88(S 02 S 02), S214-S219. https://doi.org/10.1055/a-2736-6561
Vancouver
Köppe J, Schiel A, Gerlinger C, Götte H, Edelmann D, Erdmann S. Integration of Real-World Data into Clinical Trials: An Interdisciplinary Discussion from Regulatory and Practical Perspectives. Das Gesundheitswesen. 2026;88(S 02 S 02):S214-S219. doi:10.1055/a-2736-6561
BibTeX
@article{Kppe2026,
author = {Köppe, Jeanette and Schiel, Anja and Gerlinger, Christoph and Götte, Heiko and Edelmann, Dominic and Erdmann, Stella},
title = {Integration of Real-World Data into Clinical Trials: An Interdisciplinary Discussion from Regulatory and Practical Perspectives},
journal = {Das Gesundheitswesen},
year = {2026},
volume = {88},
number = {S 02 S 02},
pages = {S214--S219},
doi = {10.1055/a-2736-6561}
}
EUVIMED